Page 2 - Ichnos Sciences News Today

Dr. Gabriela Gruia to assume the role of interim Chief Medical OfficerJason Kim to assume the role of President and Chief Financial OfficerKristen Quigley...

02.08.2023 - Dr. Gabriela Gruia to assume the role of interim Chief Medical OfficerJason Kim to assume the role of President and Chief Financial OfficerKristen Quigley to assume the role of Chief Operating OfficerDr. Grace Kim to assume the role of Chief ... Seite 1

NEW YORK, June 26, 2023 /PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific an...

PRESS RELEASE Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio ... | May 5, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A ... | April 28, 2023

/PRNewswire/ -- The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.coms offering....

The FDA announced several regulatory actions the past few weeks. Here is an overview of decisions that may be relevant to your practice.

/PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies in oncology, today announced...

/PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in...

Patients with moderate to severe atopic dermatitis showed promising results during and up to 20 weeks after treatment in a clinical trial evaluating rocatinlimab, according to a study. “I think [rocatinlimab] will be the next huge, big advance,” Emma Guttman-Yassky, MD, PhD, the Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the